CorMedix Reports 4,829% Revenue Growth and Positive Turnaround in Q2 2025 Financials

CorMedix Inc. (NYSE: CRMD) has experienced a significant transformation in its financial landscape during Q2 2025, following the commercial launch of its product, DefenCath.

Positive Aspects:

• Revenue Growth: Net sales surged to $39.7 million for the three months ended June 30, 2025, compared to $806,119 in the same period last year, marking a 4,829% increase. For the six months, revenue reached $78.8 million.
• Profitability: The company reported net income of $19.8 million for Q2 2025, a significant turnaround from a net loss of $14.2 million year-over-year. Year-to-date, net income stands at $40.5 million, contrasting with a loss of $28.6 million in 2024.
• Asset Position: CorMedix improved its cash position significantly, with cash and cash equivalents totaling approximately $159.3 million as of June 30, 2025, up from $40.7 million at the end of 2024.
• Equity Raise: The company successfully raised $82.4 million from a public offering of common stock, which will support growth initiatives and operational expenses.

Negative Aspects:

• High Operating Expenses: Total operating expenses increased to $18.3 million for Q2 2025, compared to $15.6 million last year. Research and development costs rose by 275% to $2.4 million.
• Variable Consideration Adjustment: A recent adjustment in the estimated variable considerations related to Medicaid and commercial rebates negatively impacted net income by $2.0 million in Q2 2025.
• Accrued Liabilities: As of June 30, 2025, total accrued reserves related to variable considerations were approximately $23.1 million, raising concerns over future revenue realizations.

Key Statistics:

• Net Income (Q2 2025): $19,827,981
• Revenue Growth (Q2 2025 vs. 2024): +4,829%
• Cash and Cash Equivalents (June 2025): $159,308,966
• Net Cash Provided by Operating Activities (H1 2025): $49,728,317
• Total Assets (June 2025): $252,599,103

Recent Developments:

• The acquisition of Melinta Therapeutics is in progress, with an expected close in September 2025, involving a cash payment of $260 million.
• Convertible senior notes worth $150 million are planned, with proceeds expected to support the Melinta acquisition and general corporate needs.

This quarterly report highlights the significant strides made by CorMedix in expanding its product offerings, increasing revenues, and enhancing its financial position, although it continues to grapple with elevated operational costs and accrued liabilities.